Columvi (Glofitamab) Injection 2.5mg/10mg | Roche China | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

Generic Information: Columvi (glofitamab) — Roche, China-Mainland Version

Columvi is the originator brand of glofitamab, a CD20×CD3 bispecific antibody developed by Roche. It uses a distinctive "2:1" format — two CD20-binding regions and one CD3-binding region — which gives it strong B-cell targeting while engaging T cells to attack lymphoma cells. The China-Mainland version is supplied as an injection in two strengths: 2.5 mg/2.5 mL and 10 mg/10 mL, for dilution and intravenous infusion, manufactured by Roche.

What Is Columvi Used For?

Columvi is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In China it is indicated for adult patients with relapsed or refractory DLBCL not otherwise specified, used in combination with gemcitabine and oxaliplatin for patients who are not candidates for autologous stem-cell transplantation. It is the first fixed-duration bispecific antibody approved for this population.

How Does Columvi Work?

Glofitamab is a T-cell-engaging bispecific antibody. One arm binds CD20 on B cells, including malignant lymphoma cells, while the other arm binds CD3 on T cells. This brings the patient's own T cells directly into contact with lymphoma cells, triggering the T cells to destroy them. The 2:1 CD20-to-CD3 design increases the strength of binding to B cells and enhances tumour-cell killing.

Indications

In China, Columvi is indicated, in combination with gemcitabine and oxaliplatin, for adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified who are not eligible for autologous stem-cell transplantation. Treatment is given as a fixed-duration course rather than continuous therapy until progression.

Dosage

Columvi is given by intravenous infusion with step-up dosing in the first cycle to reduce the risk of cytokine release syndrome (CRS). Patients receive premedication before each infusion. The 2.5 mg/2.5 mL vial is used for the initial step-up doses, and the 10 mg/10 mL vial is used for the full treatment doses. The exact schedule is determined by the treating physician.

Side Effects

The most common side effect is cytokine release syndrome (CRS), which can cause fever, low blood pressure and a fast heart rate. Other common effects include infections, fatigue, low blood counts and infusion-related reactions. Patients are monitored closely during the step-up dosing phase, and premedication is used to reduce these risks.

Storage

Columvi vials are stored refrigerated at 2°C to 8°C and protected from light. GLT ships through validated cold-chain logistics with batch documentation and a certificate of analysis enclosed for every order.

Why Choose China-Sourced Columvi?

Sourcing Columvi from the China market offers a substantial cost advantage over Western list prices. In the United States a single 10 mg vial is priced several times higher than the China-Mainland version, and GLT's China-sourced supply is typically priced roughly 60%–70% below the US list price. Compared with several European markets, the China-Mainland version is also considerably more affordable. GLT supplies the genuine, fully labelled Roche product with verified batch documentation, cold-chain logistics and responsive support for both institutions and individual patients.

How to Order

To order Columvi (glofitamab) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We confirm stock, vial size and cold-chain delivery timelines to your country, supporting both healthcare institutions and individual patients.

FAQ

Is Columvi a CAR-T therapy? No. Columvi is an off-the-shelf bispecific antibody that is given as a fixed-duration intravenous infusion, whereas CAR-T therapy uses a patient's own genetically modified T cells. Both are used for relapsed or refractory DLBCL, but Columvi does not require cell collection or manufacturing.

Does Columvi require cold storage? Yes. It is a refrigerated biologic shipped by validated cold chain at 2°C to 8°C until use.

Is the China-Mainland version of Columvi the same product? Yes. It is the same glofitamab molecule from Roche, supplied in the 2.5 mg/2.5 mL and 10 mg/10 mL vials with the China-Mainland label.

Related Oncology Products

Isadx (Ixazomib) 4mg | Generic Proteasome Inhibitor | BigBear Pharmaceutical Co., Ltd. | GLT

Generic ixazomib (oral proteasome inhibitor) by BigBear Pharmaceutical Co., Ltd. (Laos) — an affordable alternative...

Mozobil (Plerixafor) 24mg/1.2mL Injection China | Sanofi | GLT

Plerixafor (Mozobil) 24mg/1.2mL single-dose vial, CXCR4 antagonist for haematopoietic stem-cell mobilization in NHL and multiple...

Ponatinib (Ponaxen) 15mg/45mg Tablets | Bangladesh Generic | GLT

Generic BCR-ABL TKI for T315I-positive CML and Ph+ ALL

Ponatinib (LuciPona) 15mg/45mg Tablets | Laos Generic | GLT

Generic BCR-ABL TKI for T315I-positive CML and Ph+ ALL

PHOIXAZ (Ixazomib) 4mg | Generic Proteasome Inhibitor | Pharma 2 Vientiane | GLT

Generic ixazomib (oral proteasome inhibitor) by Pharma 2 Vientiane (Laos) — an affordable alternative to...

LuciXaz (Ixazomib) 4mg | Generic Proteasome Inhibitor | Lucius Pharmaceuticals (Lao) Co., Ltd. | GLT

Generic ixazomib (oral proteasome inhibitor) by Lucius Pharmaceuticals (Lao) Co., Ltd. (Laos) — an affordable...